How Lipfendra, Inclisiran, and New Guidelines Are Changing Cholesterol Management

<ul><li>A new analysis found that the twice-yearly cholesterol medication inclisiran reduced LDL cholesterol by 49% more than placebo.</li><li>The FDA approved Lipfendra, the first oral PCSK9 inhibit…